Горбань Н. А.¹, Михайленко Д. С.²

¹ФГБУ «Центральная клиническая больница с поликлиникой» Управления делами Президента Российской Федерации; Россия, 121359 Москва, ул. Маршала Тимошенко, 15;

²ФГБНУ «Медико-генетический научный центр им. акад. Н. П. Бочкова»; Россия, 115522 Москва, ул. Москворечье, 1

1. Kovacs G., Akhtar M., Beckwith B. et al. The Heidelberg classification of renal cell tumours J Pathol 1997;183:131–3.

2. Fleming S. Genetics of kidney tumours. Forum (Genova) 1998;8(2):176–84.

3. Eble J.N. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, Oxford: IARC Press, Oxford University Press, 2004.

4. Moch H., Humphrey P.A., Ulbright T.M., Reuter V.E. WHO Classification of Tumours of the Urinary System and Male Genital Organs, 4th edn. Lyon: IARC Press, 2016.

5. WHO Classification of tumours of the urinary system and male genital organs (ed. 5). Lyon: International Agency for Research on Cancer, 2022.

6. Delahunt B., Cheville J.C., Martignoni G. et al. Members of the ISUP Renal Tumor Panel. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 2013;37(10):1490–504. DOI: 10.1097/PAS.0b013e318299f0fb

7. Tretiakova M., Mehta V., Kocherginsky M. et al. Predominantly cystic clear cell renal cell carcinoma and multilocular cystic renal neoplasm of low malignant potential form a low-grade spectrum. Virchows Arch 2018;473(1):85–93. DOI: 10.1007/s00428-018-2371-8

8. Williamson S.R., Halat S., Eble J.N. et al. Multilocular cystic renal cell carcinoma: similarities and differences in immunoprofile compared with clear cell renal cell carcinoma. Am J Surg Pathol 2012;36(10):1425–33. DOI: 10.1097/PAS.0b013e31825b37f0

9. Westerman M.E., Cheville J.C., Lohse C.M. et al. Long-term outcomes of patients with low grade cystic renal epithelial neoplasms. Urology 2019;133:145–50. DOI: 10.1016/j.urology.2019.07.017

10. Skenderi F., Ulamec M., Vanecek T. et al. Warthin-like papillary renal cell carcinoma: Clinicopathologic, morphologic, immunohistochemical and molecular genetic analysis of 11 cases. Ann Diagn Pathol 2017;27:48–56. DOI: 10.1016/j.anndiagpath.2017.01.005

11. Kunju L.P., Wojno K., Wolf J.S.Jr. et al. Papillary renal cell carcinoma with oncocytic cells and nonoverlapping low grade nuclei: expanding the morphologic spectrum with emphasis on clinicopathologic, immunohistochemical and molecular features. Hum Pathol 2008;39(1):96–101. DOI: 10.1016/j.humpath.2007.05.016

12. Al-Obaidy K..I, Eble J.N., Nassiri M. et al. Recurrent KRAS mutations in papillary renal neoplasm with reverse polarity. Mod Pathol 2020;33(6):1157–64. DOI: 10.1038/s41379-019-0362-1

13. Chen Y.B., Mirsadraei L., Jayakumaran G. et al. Somatic mutations of TSC2 or MTOR characterize a morphologically distinct subset of sporadic renal cell carcinoma with eosinophilic and vacuolated cytoplasm. Am J Surg Pathol 2019;43(1):121–31. DOI: 10.1097/PAS.0000000000001170

14. Tjota M., Chen H., Parilla M. et al. Eosinophilic renal cell tumors with a TSC and MTOR gene mutations are morphologically and immunohistochemically heterogenous: clinicopathologic and molecular study. Am J Surg Pathol 2020;44(7):943–54. DOI: 10.1097/PAS.0000000000001457

15. Trpkov K., Williamson S.R., Gao Y. et al. Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive): A distinct entity? Histopathology 2019;75(2):174–84. DOI: 10.1111/his.13865

16. Siadat F., Trpkov K. ESC, ALK, HOT and LOT: Three letter acronyms of emerging renal entities knocking on the door of the WHO Classification. Cancers (Basel) 2020 ;12(1):168. DOI: 10.3390/cancers12010168

17. Guo Q., Liu N., Wang F. et al. Characterization of a distinct lowgrade oncocytic renal tumor (CD117-negative and cytokeratin 7-positive) based on a tertiary oncology center experience: the new evidence from China. Virchows Arch 2021;478(3):449–58. DOI: 10.1007/s00428-020-02927-0

18. Dhakal H.P., McKenney J.K., Khor L.Y. et al. Renal neoplasms with overlapping features of clear cell renal cell carcinoma and clear cell papillary renal cell carcinoma: A clinicopathologic study of 37 cases from a single institution. Am J Surg Pathol 2016;40(2):141–54. DOI: 10.1097/PAS.0000000000000583

19. Williamson S.R., Gupta N.S., Eble J.N. et al. Clear cell renal cell carcinoma with borderline features of clear cell papillary renal cell carcinoma: Combined morphologic, immunohistochemical, and cytogenetic analysis. Am J Surg Pathol 2015;39(11):1502–10. DOI: 10.1097/PAS.0000000000000514

20. Wang K., Zarzour J., Rais-Bahrami S., Gordetsky J. Clear cell papillary renal cell carcinoma: New clinical and imaging characteristics. Urology 2017;103:136–41. DOI: 10.1016/j.urology.2016.12.002

21. Guo J., Tretiakova M.S., Troxell M.L. et al. Tuberous sclerosisassociated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients. Am J Surg Pathol 2014;38(11):1457–67. DOI: 10.1097/PAS.0000000000000248

22. Schreiner A., Daneshmand S., Bayne A. et al. Distinctive morphology of renal cell carcinomas in tuberous sclerosis. Int J Surg Pathol 2010;18(5):409–18. DOI: 10.1177/1066896909333510

23. Trpkov K., Hes O., Bonert M. et al. Eosinophilic, solid, and cystic renal cell carcinoma: Clinicopathologic study of 16 unique, sporadic neoplasms occurring in women. Am J Surg Pathol 2016;40(1):60–71. DOI: 10.1097/PAS.0000000000000508

24. Palsgrove D.N., Li Y., Pratilas C.A. et al. Eosinophilic solid and cystic (ESC) renal cell carcinomas harbor TSC mutations: Molecular analysis supports an expanding clinicopathologic spectrum. Am J Surg Pathol 2018;42(9):1166–81. DOI: 10.1097/PAS.0000000000001111

25. Akgul M., Cheng L. Immunophenotypic and pathologic heterogeneity of unclassified renal cell carcinoma: A study of 300 cases. Hum Pathol 2020;102:70–8. DOI: 10.1016/j.humpath.2020.06.007

26. Argani P., Zhang L., Reuter V.E. et al. RBM10-TFE3 renal cell carcinoma: A potential diagnostic pitfall due to cryptic intrachromosomal Xp11.2 inversion resulting in false-negative TFE3 FISH. Am J Surg Pathol 2017;41(5):655–62. DOI: 10.1097/PAS.0000000000000835

27. Argani P., Antonescu C.R., Couturier J. et al. PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1) (p11.2;q21). Am J Surg Pathol 2002;26(12):1553–66. DOI: 10.1097/00000478-200212000-00003

28. Argani P., Aulmann S., Karanjawala Z. et al. Melanotic Xp11 translocation renal cancers: a distinctive neoplasm with overlapping features of PEComa, carcinoma, and melanoma. Am J Surg Pathol 2009;33(4):609–19. DOI: 10.1097/PAS.0b013e31818fbdff

29. Argani P., Aulmann S., Illei P.B. et al. A distinctive subset of PEComas harbors TFE3 gene fusions. Am J Surg Pathol 2010;34(10):1395–406. DOI: 10.1097/PAS.0b013e3181f17ac0

30. Argani P., Reuter V.E., Zhang L. et al. TFEB-amplified renal cell carcinomas: An aggressive molecular subset demonstrating variable melanocytic marker expression and morphologic heterogeneity. Am J Surg Pathol 2016;40(11):1484–95. DOI: 10.1097/PAS.0000000000000720

31. Skala S.L., Xiao H., Udager A.M. et al. Detection of 6 TFEBamplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays. Mod Pathol 2018;31(1):179–97. DOI: 10.1038/modpathol.2017.99

32. Gupta S., Argani P., Jungbluth A.A. et al. TFEB expression profiling in renal cell carcinomas: Clinicopathologic correlations. Am J Surg Pathol 2019;43(11):1445–61. DOI: 10.1097/PAS.0000000000001307

33. Xia Q.Y., Wang X.T., Fang R. et al. Clinicopathologic and molecular analysis of the TFEB fusion variant reveals new members of TFEB translocation renal cell carcinomas (RCCs): Expanding the genomic spectrum. Am J Surg Pathol 2020;44(4):477–89. DOI: 10.1097/PAS.0000000000001408

34. Caliò A., Harada S., Brunelli M. et al. TFEB rearranged renal cell carcinoma. A clinicopathologic and molecular study of 13 cases. Tumors harboring MALAT1-TFEB, ACTB-TFEB, and the novel NEAT1-TFEB translocations constantly express PDL1. Mod Pathol 2021;34(4):842–50. DOI: 10.1038/s41379-020-00713-6

35. Harrison W.J., Andrici J., Maclean F. et al. Fumarate hydratasedeficient uterine leiomyomas occur in both the syndromic and sporadic settings. Am J Surg Pathol 2016;40(5):599–607. DOI: 10.1097/PAS.0000000000000573

36. Watanabe I.C., Billis A., Guimarães M.S. et al. Renal medullary carcinoma: report of seven cases from Brazil. Mod Pathol 2007;20(9):914–20. DOI: 10.1038/modpathol.3800934

37. O’Donnell P.H., Jensen A., Posadas E.M. et al. Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy. Nat Rev Urol 2010;7(2):110–4. DOI: 10.1038/nrurol.2009.255

38. Agaimy A. The expanding family of SMARCB1(INI1)-deficient neoplasia: implications of phenotypic, biological, and molecular heterogeneity. Adv Anat Pathol 2014;21(6):394–410. DOI: 10.1097/PAP.0000000000000038

39. Debelenko L.V., Raimondi S.C., Daw N. et al. Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol 2011;24(3):430–42. DOI: 10.1038/modpathol.2010.213

40. Sugawara E., Togashi Y., Kuroda N. et al. Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibodyenhanced polymer method. Cancer 2012;118(18):4427–36. DOI: 10.1002/cncr.27391

41. Kuroda N., Trpkov K., Gao Y. et al. ALK rearranged renal cell carcinoma (ALK-RCC): A multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217. Mod Pathol 2020;33(12):2564–79. DOI: 10.1038/s41379-020-0578-0

42. Pal S.K., Bergerot P., Dizman N. et al. Responses to alectinib in ALK-rearranged papillary renal cell carcinoma. Eur Urol 2018;74(1):124–8. DOI: 10.1016/j.eururo.2018.03.032

43. Shah R.B., Stohr B.A., Tu Z.J. et al. “Renal cell carcinoma with leiomyomatous stroma” harbor somatic mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and molecular characterization of 18 sporadic tumors supports a distinct entity. Am J Surg Pathol 2020;44(5):571–81. DOI: 10.1097/PAS.0000000000001422

44. DiNatale R.G., Gorelick A.N., Makarov V. et al. Putative drivers of aggressiveness in TCEB1-mutant renal cell carcinoma: An emerging entity with variable clinical course. Eur Urol Focus 2021;7(2):381–9. DOI: 10.1016/j.euf.2019.11.013